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Abstract: Circulating microRNAs (miRNAs) hold great potential as novel diagnostic markers
for acute coronary syndrome (ACS). This study sought to identify plasma miRNAs that are
differentially expressed in young ACS patients (mean age of 38.5 ± 4.3 years) and evaluate their
diagnostic potentials. Small RNA sequencing (sRNA-seq) was used to profile plasma miRNAs.
Discriminatory power of the miRNAs was determined using receiver operating characteristic
(ROC) analysis. Thirteen up-regulated and 16 down-regulated miRNAs were identified in young
ACS patients. Quantitative reverse transcription-polymerase chain reaction (qRT-PCR) validation
showed miR-183-5p was significantly up-regulated (8-fold) in ACS patients with non-ST-segment
elevated myocardial infarction (NSTEMI) whereas miR-134-5p, miR-15a-5p, and let-7i-5p were
significantly down-regulated (5-fold, 7-fold and 3.5-fold, respectively) in patients with ST-segment
elevated myocardial infarction (STEMI), compared to the healthy controls. MiR-183-5p had a high
discriminatory power to differentiate NSTEMI patients from healthy controls (area under the curve
(AUC) of ROC = 0.917). The discriminatory power for STEMI patients was highest with let-7i-5p
(AUC = 0.833) followed by miR-134-5p and miR-15a-5p and this further improved (AUC = 0.935)
with the three miRNAs combination. Plasma miR-183-5p, miR-134-5p, miR-15a-5p and let-7i-5p are
deregulated in STEMI and NSTEMI and could be potentially used to discriminate the two ACS forms.
Keywords: circulating microRNAs; acute coronary syndrome; STEMI; NSTEMI
1. Introduction
Coronary artery disease (CAD) is a leading cause of death worldwide. Clinical presentations
of CAD include silent ischemia, stable angina pectoris, unstable angina, myocardial infarction, heart
failure, and sudden death [1]. Acute coronary syndrome (ACS) refers to any group of clinical symptoms
compatible with acute myocardial ischemia and includes unstable angina pectoris, ST-segment elevated
myocardial infarction (STEMI) and non-ST-segment elevated myocardial infarction (NSTEMI) [2].
Between the years 2011 and 2013, approximately 15,000 ACS cases were reported in Malaysia, with
more than 75% afflicting patients older than 50 years of age. To date, the rates of myocardial infarction,
readmission of patients with ACS and death remain high, underscoring the need for more aggressive
health awareness, education, and non-pharmacological approaches to counter this rising prevalence of
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ACS as well as innovative early and reliable biomarkers to facilitate rapid and more accurate diagnosis
and subsequent treatment.
Electrocardiography (ECG) and cardiac troponins are conventional tests used for the diagnosis
of ACS. ECG detects transient ST-segment elevations, dynamic T-wave changes, and ST depressions
during acute events [3]; however, ECG patterns that are diagnostic of ACS are not present in
approximately half of the ACS patients at the time of presentation in an emergency department [4].
Hence a significant proportion of ACS may elude detection by ECG alone. For this reason,
the diagnosis of ACS remains a challenge especially in individuals without clear symptoms or
electrocardiographic features.
Cardiac troponin I or T are not detectable in the blood of healthy individuals and are more
predictive of myocardial necrosis compared to creatine kinase-myocardial band isoenzyme (CK-MB) [5].
However, cardiac troponins may not be elevated consistently at the onset of myocardial infarction,
which can hinder early diagnosis [6]. Moreover, changes in troponin levels also occur under
conditions other than ACS (including chronic renal failure, cerebrovascular accidents, acute pulmonary
embolism, hypertensive crisis, tachy- or bradyarrhythmias, acute inflammatory myocarditis, and
skeletal myopathies) [7]. Misinterpretation of detectable troponin levels may lead to confusion of
diagnosis and inappropriate choice of therapy. Hence, there is a need to identify additional biomarkers
to support accurate clinical diagnosis and management.
MicroRNAs (miRNAs) have been identified and advocated as biomarkers for the diagnosis and/or
prognosis of cardiovascular diseases such as ischemic heart disease, heart failure, stroke, and CAD [8,9].
They are short (≈22 nucleotides), non-coding RNAs that regulate genes post-transcriptionally by
translational repression following partial complementary binding to target sites on untranslated
regions of mRNAs [10–12]. MiRNAs play important roles in various biological and cellular processes
by regulating the expression of their target genes in signaling pathways. They are present in tissues
and in the circulation; aberrations of miRNAs expression levels occur in various diseases including
cancer and cardiovascular disorders [13–16]. In the latter, for example, the expressions of miR-134,
miR-198, and miR-370 are increased in patients with unstable angina pectoris and acute pulmonary
embolism [17,18]. The use of circulating miRNAs for the diagnosis of diseases is reliable as they
are stable in plasma or serum and their expressions can be easily quantified by quantitative reverse
transcription-polymerase chain reaction (qRT-PCR). In this regard, it would be advantageous to detect
early alterations in the levels of circulating miRNAs for the diagnosis of ACS during the early onset
of symptoms. This is exemplified by the detection of circulating miRNAs within three hours of
symptom onset and in patients with initially negative troponin levels [19]. Specifically, peak expression
levels of miR-19b-5p, miR-134-5p, and miR-186-5p can be detected approximately ten hours after the
onset of chest pain in patients with acute myocardial infarction [20]. Moreover, their presence also
positively correlates with cardiac troponin I. Given that a single miRNA can have various targets
and in view of the cooperative mechanisms involved, a multi panel approach of miRNAs detection
could further increase diagnostic efficiency. Taken in conjunction, the available information suggests
that circulating levels of certain miRNAs have strong potentials as biomarkers for the diagnosis of
cardiovascular diseases.
In the diagnosis of ACS, the identification and evaluation of the use of circulating miRNAs have
thus far focused on patients of higher age groups, as older people are more at risk for ACS where
its prevalence is indeed higher in the elderly [20–22]. Apart from age, other risk factors for ACS
include smoking, diabetes, hypertension, obesity, and hypercholesterolemia [23,24]. In Malaysia,
approximately 23% of ACS cases involved individuals below 50 years of age and the majority of these
patients were male (~80%) [25]. In addition, a retrospective review in the northern region of Malaysia
further revealed that 55% of these patients had premature CAD [26]. The increasing prevalence of ACS
in younger individuals could be linked to the continuous rise in obesity, diabetes, and hypertension in
that age group in Malaysia. The occurrence of ACS in young individuals is uncommon and is often
overlooked during clinical examination but the prognosis is more favorable compared to that of elderly
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patients [27,28]. Hence, there is a need to identify suitable early biomarkers for young ACS patients as
they are often under-diagnosed due to a lower clinical suspicion. The present study sought to achieve
this by performing small RNA sequencing to identify plasma miRNAs in young ACS patients.
2. Results
2.1. Baseline Characteristics of the Study Population
Assessment of clinical characteristics revealed no statistical difference between the healthy control
subjects with the ACS subgroups for most of the clinical variables measured except for significantly
higher plasma levels of high-density lipoproteins (HDL) and lower white blood cell counts (WBC)
in the healthy controls compared to the ACS group (Tables 1 and 2). This is anticipated as lower
plasma HDL level in patients is associated with the incidence of premature CAD [26,29]. There were
also no significant differences in the age (p = 0.16) and CK-MB levels (p = 0.69) between the ACS and
healthy subjects. As expected, patients with STEMI had higher troponin I and CK-MB levels compared
to NSTEMI subjects because the degree of coronary occlusion is worse in STEMI (Tables 1 and 2).
The percentage of patients prescribed with medications was also higher in the STEMI than in the
NSTEMI group. This reflects that ACS with STEMI, which has a worse outcome, warrants more
aggressive treatment.
Table 1. Clinical characteristics of acute coronary syndrome (ACS) patients and control subjects used
for small-RNA sequencing.
STEMI Patients
(n = 11)
NSTEMI Patients
(n = 3)
Healthy Controls
(n = 14) p-Value
Age (years) 36.36 ± 1.73 39.67 ± 2.96 35.55 ± 1.92 0.5851
Male sex (% male) 11 (100) 3 (100) 14 (100)
Health history, n (%):
Alcohol drinker 1 (9.09) 0 (0) 0 (0)
Smokers 11 (100) 1 (33.33) 0 (0)
Morbid Obesity 0 (0) 0 (0) 0 (0)
Familial Hypercholesterolemia 1 (9.09) 0 (0) 0 (0)
Hypertension 4 (36.36) 0 (0) 1 (7.14)
Diabetes mellitus 1 (9.09) 1 (33.33) 1 (7.14)
Family History of CVD 7 (63.64) 2 (66.67) 0 (0)
# Medications, n (%):
Acetylsalicylic acid 9 (81.82) 2 (66.67) 0 (0)
Lipid lowering drugs 10 (90.91) 2 (66.67) 0 (0)
Beta-blocker 6 (54.55) 1 (33.33) 0 (0)
Others 2 (18.18) 1 (33.33) 0 (0)
Laboratory tests
WBC (×109/L) 12.63 ± 1.14 11.90 ± 1.79 8.68 ± 0.56 0.0110 *
Glucose (mmol/L) 6.19 ± 0.55 8.10 ± 2.61 6.26 ± 0.58 0.4087
TC (mmol/L) 4.83 ± 0.40 5.07 ± 0.45 5.26 ± 0.44 0.7581
HDL (mmol/L) 0.96 ± 0.07 0.78 ± 0.10 1.19 ± 0.09 0.0329 *
LDL (mmol/L) 3.14 ± 0.37 3.39 ± 0.30 3.33 ± 0.38 0.5610
TG (mmol/L) 1.61 ± 0.22 1.97 ± 0.52 1.65 ± 0.20 0.7493
Troponin I (ng/mL) 11.78 ± 4.89 1.94 ± 0.69 ND ND
Creatine kinase (U/L) 1859.67 ± 619.44 496.00 ± 337.93 641.3 ± 495.96 0.1037
CK-MB (µg/L) 88.33 ± 25.69 28.00 ± 25.03 4.03 ± 2.07 0.0698
Abbreviations: CVD, cardiovascular disease; WBC, white blood cells; TC, total cholesterol; HDL, high-density
lipoproteins; LDL, low-density lipoproteins; CK-MB, creatine kinase-myocardial band; ND, not determined.
# Medications were given on admission/in the ward; * significantly different compared to healthy control.
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Table 2. Clinical characteristics of ACS patients and control subjects used for quantitative reverse
transcription-polymerase chain reaction (qRT-PCR) validation.
STEMI Patients
(n = 9)
NSTEMI Patients
(n = 5)
Healthy Controls
(n = 12) p-Value
Age (years) 37.78 ± 1.29 37.80 ± 2.15 36.80 ± 1.83 0.8912
Male sex (% male) 9 (100) 5 (100) 12 (100)
Health history, n (%):
Alcohol drinker 1 (11.11) 0 (0) 0 (0)
Smokers 8 (88.89) 2 (40.00) 0 (0)
Morbid Obesity 0 (0) 0 (0) 0 (0)
Familial Hypercholesterolemia 0 (0) 0 (0) 0 (0)
Hypertension 0 (0) 0 (0) 1 (8.33)
Diabetes mellitus 0 (0) 2 (40.00) 1 (8.33)
Family History of CVD 5 (55.56) 3 (60.00) 0 (0)
# Medications, n (%):
Acetylsalicylic acid 8 (88.89) 3 (60.00) 0 (0)
Lipid lowering drugs 8 (88.89) 3 (60.00) 0 (0)
Beta-blocker 7 (77.78) 2 (40.00) 0 (0)
Others 1 (11.11) 1 (20.00) 0 (0)
Laboratory tests
WBC (×109/L) 13.22 ± 1.63 12.02 ± 1.17 9.13 ± 0.74 0.0587
Glucose (mmol/L) 6.33 ± 0.49 9.04 ± 2.00 7.10 ± 0.71 0.1979
TC (mmol/L) 5.66 ± 0.62 5.46 ± 0.41 5.62 ± 0.49 0.9685
HDL (mmol/L) 1.14 ± 0.26 0.99 ± 0.12 1.27 ± 0.09 0.0841
LDL (mmol/L) 3.55 ± 0.68 3.80 ± 0.37 3.58 ± 0.46 0.7561
TG (mmol/L) 2.04 ± 0.29 1.46 ± 0.16 1.72 ± 0.27 0.9510
Troponin I (ng/mL) 6.29 ± 6.24 5.97 ± 4.23 ND ND
Creatine kinase (U/L) 1526.89 ± 461.82 760.20 ± 452.37 910.50 ± 721.50 0.3601
CK-MB (µg/L) 140.28 ± 83.35 35.20 ± 17.47 5.55 ± 2.45 0.2262
Abbreviations: CVD, cardiovascular disease; WBC, white blood cells; TC, total cholesterol; HDL, high-density
lipoproteins; LDL, low-density lipoproteins; CK-MB, creatine kinase-myocardial band; ND, not determined;
# Medications were given on admission/in the ward.
2.2. Detection of miRNA Expression in Plasma of Young ACS by Small RNA Sequencing (sRNA-seq)
On the average, 58,000 reads mapped to the human genome were obtained per sample and after
applying the filter, an average of 9086 clean reads were obtained (Figure 1A). Length distribution
analysis showed that most reads were in the range of 18 to 24 nt in plasma pools of both the ACS
patients and the healthy controls, which is consistent with the common length of miRNAs [30,31].
MiRNAs were the major component of the small RNAs population in the dataset (Figure 1B). MiRDeep2
analysis identified a total of 1702 miRNAs, of which 752 are known, from the pooled samples. On the
average, 38.5% of mapped nr-reads were aligned to annotated miRNA genes in the reference genome
(Figure 1C). In the STEMI group, a total of 166 miRNAs with reads above 200 and present in more
than five subjects were retained in the list used for differential expression analysis using DESeq2
(https://bioconductor.org/packages/release/bioc/html/DESeq2.html) [32]. A cut-off of 10% false
discovery rate (FDR) yielded 13 up-regulated and 16 down-regulated miRNAs in the STEMI group
(Table 3). MiRNAs with more than 1.5-fold changes in expression (i.e., miR-183-5p, miR-15a-5p,
miR-375, miR-1307-5p, miR-134-5p, and let-7i-5p) were selected for subsequent qRT-PCR validation.
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Table 3. Significantly deregulated miRNAs in ST-segment elevated myocardial infarction (STEMI)
patients compared to healthy controls.
miRNA BaseMean
Log2 Fold
Change
Fold
Change Regulation p-Value
Adjusted
p-Value
hsa-miR-183-5p_MIMAT0000261 133.430 2.232 4.699 Up 0.0000856 0.00317
hsa-miR-19a-5p_MIMAT0004490 269.760 1.732 3.322 Up 0.00379 0.03740
hsa-miR-15a-5p_MIMAT0000068 466.668 1.680 3.205 Up 0.00252 0.02723
hsa-miR-101-5p_MIMAT0004513 1857.448 1.053 2.075 Up 0.00942 0.07019
hsa-miR-101-3p_MIMAT0000099 1857.448 1.053 2.075 Up 0.00942 0.07019
hsa-miR-103a-3p_MIMAT0000101 5231.824 1.047 2.066 Up 0.00250 0.02723
hsa-miR-107_MIMAT0000104 5231.824 1.047 2.066 Up 0.00250 0.02723
hsa-miR-103a-2-5p_MIMAT0009196 5231.824 1.047 2.066 Up 0.00250 0.02723
hsa-miR-16-5p_MIMAT0000069 5923.048 1.037 2.052 Up 0.01173 0.07091
hsa-miR-16-5p_MIMAT0000069 5925.776 1.036 2.051 Up 0.01180 0.07091
hsa-miR-25-5p_MIMAT0004498 18,099.042 0.918 1.890 Up 0.00473 0.04118
hsa-miR-30e-5p_MIMAT0000692 2296.889 0.897 1.862 Up 0.01612 0.08520
hsa-miR-30a-5p_MIMAT0000087 3027.454 0.849 1.801 Up 0.01892 0.09657
CM000680.1_15285_novel 3128.361 −2.349 5.093 Down 0.0000004213 0.00006
CM000668.1_36492_novel 1075.400 −2.202 4.602 Down 0.00122 0.02578
hsa-miR-1307-5p_MIMAT0022727 404.613 −2.191 4.565 Down 0.00003364 0.00166
hsa-miR-375_MIMAT0000728 1029.877 −2.058 4.164 Down 0.00036 0.01060
hsa-let-7i-5p_MIMAT0000415 58,413.753 −1.910 3.759 Down 0.000009499 0.00070
hsa-miR-134-5p_MIMAT0000447 156.437 −1.802 3.486 Down 0.00258 0.02723
hsa-miR-328-5p_MIMAT0026486 116.074 −1.657 3.154 Down 0.01198 0.07091
hsa-let-7f-5p_MIMAT0000067 58,027.774 −1.445 2.723 Down 0.00046 0.01131
hsa-miR-320a_MIMAT0000510 4133.844 −1.432 2.698 Down 0.00185 0.02723
CM000668.1_35903_novel 361.953 −1.362 2.570 Down 0.01030 0.07084
hsa-miR-181b-5p_MIMAT0000257 1130.724 −1.259 2.393 Down 0.00413 0.03818
hsa-miR-181b-5p_MIMAT0000257 1155.505 −1.232 2.349 Down 0.00159 0.02723
hsa-miR-409-5p_MIMAT0001638 3315.486 −1.158 2.232 Down 0.00948 0.07019
hsa-miR-744-5p_MIMAT0004945 1996.177 −0.973 1.963 Down 0.01053 0.07084
hsa-miR-181a-5p_MIMAT0000256 34,050.461 −0.656 1.575 Down 0.01379 0.07560
hsa-miR-181a-5p_MIMAT0000256 34,050.461 −0.656 1.575 Down 0.01379 0.07560
2.3. Quantitative RT-PCR (qRT-PCR) Validation of miRNAs Expression
A second cohort of young male patients was recruited for qRT-PCR validation (Table 2), including
two STEMI, two NSTEMI patients, and nine healthy controls from the original sRNA-seq cohort.
Validation by qRT-PCR revealed a significant 8-fold up-regulation of miR-183-5p in NSTEMI patients
(p = 0.024) compared to healthy controls (Figure 2A). The expressions of miR-183-5p in NSTEMI
patients were also significantly higher than those of the STEMI patients (Figure 2A). In STEMI patients,
miR-134-5p, miR-15a-5p, and let-7i-5p were significantly down-regulated 5-fold (p = 0.048), 7-fold
(p = 0.015) and 3.5-fold (p = 0.013), respectively, compared to healthy controls (Figure 2B–D), whereas
miR-375 and miR-1307-5p were not significantly differentially expressed in STEMI and NSTEMI
patients compared to the healthy controls (Figure 2E,F).
Since miR-183-5p, miR-134-5p, miR-15a-5p, and let-7i-5p were deregulated significantly in
STEMI and NSTEMI patients, their expressions were compared further with those of the stable
angina patients without ACS for more than one year. The expressions of miR-183-5p, miR-134-5p,
miR-15a-5p, and let-7i-5p were not significantly deregulated in the stable angina patients compared to
healthy controls (Figure 3). One-way analysis of variance (ANOVA) analysis followed by the Tukey
multiple comparison test revealed that miR-183-5p is significantly up-regulated in NSTEMI compared
to the stable angina patients (Figure 3A). In addition, the expression of miR-15a-5p and let-7i-5p
were significantly down-regulated in patients with STEMI compared to those with stable angina
(Figure 3C,D). The expression of miR-134-5p for STEMI patients was only significantly down-regulated
when compared to healthy controls but not to the NSTEMI and stable angina groups (Figure 3B).
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as the geometric means ± 95% CI, confidence interval. p-values were calculated using one-way 
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Figure 2. MiRNAs expression in ACS subtypes. Log2 transformation of normalized relative quantity
of (A) miR-183-5p, (B) miR-134-5p, (C) miR-15a-5p, (D) let-7i-5p, (E) miR-375, and (F) miR-1307-5p in
healthy controls (n = 12), STEMI (n = 9), and NSTEMI (n = 5) patients. The expressions of the target
miRNAs were normalized to both reference miRNAs, i.e., miR-320a and miR-17-5p. Data are shown as
the geometric means ± 95% CI, confidence interval. p-values were calculated using one-way ANOVA
followed by the Tukey multiple groups comparison test; * indicates p < 0.05 compared to healthy
control individuals; and # indicates p < 0.05 compared to NSTEMI patients.
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transformation of normalized relative quantity of (A) miR-183-5p, (B) miR-134-5p, (C) miR-15a-5p, and
(D) let-7i-5p in healthy controls (n = 12), STEMI (n = 9), NSTEMI (n = 5), and stable angina (n = 11)
patients. The expressions of the target miRNAs were normalized to both reference miRNAs, i.e.,
miR-320a and miR-17-5p. Data are shown as the geometric means ± 95% CI, confidence interval.
p-values were calculated using one-way ANOVA followed by the Tukey multiple groups comparison
test; ns indicates not significant; * indicates p < 0.05 compared to healthy control individuals; # indicates
p < 0.05 compared to NSTEMI patients; φ indicates p < 0.05 and φφ, p < 0.01 compared to stable
angina patients.
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2.4. Diagnostic Power of Plasma miRNAs in STEMI and NSTEMI Patients
The diagnostic accuracy and discriminatory power of miR-183-5p, miR-134-5p, miR-15a-5p,
and let-7i-5p for patients with STEMI and NSTEMI from healthy controls was determined using
receiver operator characteristic (ROC) analysis, and illustrated by area under the curve (AUC) of
ROC (Figure 4A and Table 4). MiR-183-5p scored a very high AUC value of 0.917 (p < 0.0001;
95% CI, confidence interval 0.680 to 0.995) with sensitivity and specificity values of 100% and 75%,
respectively; this indicates a strong differentiation power of miR-183-5p for NSTEMI patients from
healthy controls. However, miR-183-5p showed weaker discriminatory power for STEMI patients with
an AUC value of 0.509 (p = 0.947; 95% CI, 0.285 to 0.731) from the healthy controls (Figure 4A(i) and
Table 4). Nevertheless, miR-134-5p, miR-15a-5p, and let-7i-5p showed better differentiation power in
discriminating STEMI patients from healthy controls with higher AUC values of 0.796 (p = 0.004; 95%
CI, 0.566 to 0.938), 0.796 (p = 0.003; 95% CI, 0.566 to 0.938), and 0.833 (p = 0.0005; 95% CI, 0.608 to 0.958),
respectively (Figure 4A(ii)–(iv), Table 4). Moreover, among these three miRNAs, the discriminatory
power of let-7i-5p was the highest with a sensitivity value of 100% and a specificity value of 67% in
differentiating STEMI patients from healthy controls (Table 4). Collectively, these findings reveal the
strong discriminatory power of miR-183-5p in NSTEMI patients and miR-134-5p, miR-15a-5p, and
let-7i-5p in STEMI patients from the healthy controls.
To investigate the discriminatory power of circulating miRNAs of ACS patients from patients
with stable angina, AUC values for their respective ROC curves were obtained (Figure 4B and
Table 5). The discriminatory power of plasma miRNAs in STEMI against stable angina patients was
highest in let-7i-5p, followed by miR-134-5p, miR-15a-5p, and miR-183-5p (Figure 4B(i) and Table 5).
In differentiating NSTEMI from stable angina patients, miR-183-5p scored the highest discriminatory
power compared to the other miRNAs, with the highest AUC value of 0.917 (p < 0.0001; 95% CI, 0.680
to 0.995), a sensitivity value of 100% and a specificity of 83% (Figure 4B(ii) and Table 5).
Table 4. Discriminatory powers of plasma miRNAs for STEMI and NSTEMI patients against healthy controls.
Patients miRNAs AUC 95% CI p-Value Sensitivity (%) Specificity (%)
STEMI
miR-183-5p 0.509 0.285 to 0.731 0.947 33.3 83.3
miR-134-5p 0.796 0.566 to 0.938 0.004 ** 66.7 83.3
miR-15a-5p 0.796 0.566 to 0.938 0.003 ** 100.0 58.3
let-7i-5p 0.833 0.608 to 0.958 0.0005 ** 100.0 66.7
miR-375 0.620 0.386 to 0.820 0.335 88.9 41.7
miR-1307-5p 0.698 0.455 to 0.880 0.103 100.0 58.3
NSTEMI
miR-183-5p 0.917 0.680 to 0.995 <0.0001 *** 100.0 75.0
miR-134-5p 0.717 0.451 to 0.904 0.144 60.0 83.3
miR-15a-5p 0.617 0.355 to 0.836 0.411 100.0 50.0
let-7i-5p 0.583 0.325 to 0.812 0.592 80.0 83.7
miR-375 0.683 0.418 to 0.882 0.207 60.0 83.3
miR-1307-5p 0.667 0.402 to 0.871 0.205 100.0 50.0
Abbreviations: AUC, area under the curve of ROC; 95% CI, confidence interval. P-values and 95% confidence intervals
(95% CI) were computed following the method of DeLong et al. (1988) [33]. ** indicates p < 0.01; ***, p < 0.001.
Table 5. Discriminatory powers of circulating miRNAs for STEMI and NSTEMI patients against stable
angina patients.
Patients miRNAs AUC 95% CI p-Value Sensitivity (%) Specificity (%)
STEMI
miR-183-5p 0.546 0.318 to 0.761 0.756 55.6 75.0
miR-134-5p 0.769 0.535 to 0.922 0.027 * 55.6 100.0
miR-15a-5p 0.907 0.700 to 0.989 <0.0001 *** 100.0 66.7
let-7i-5p 0.929 0.722 to 0.995 <0.0001 *** 100.0 81.8
NSTEMI
miR-183-5p 0.917 0.680 to 0.995 <0.0001 *** 100.0 83.3
miR-134-5p 0.633 0.370 to 0.848 0.486 40.0 100.0
miR-15a-5p 0.717 0.451 to 0.904 0.100 100.0 50.0
let-7i-5p 0.618 0.348 to 0.843 0.525 60.0 81.8
Abbreviations: AUC, area under the curve of ROC; 95% CI, confidence level. P-values and 95% CI were computed
following the method of DeLong et al. (1988) [33]. * indicates p < 0.05; ***, p < 0.001.
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Figure 4. Discriminatory power of plasma miRNAs for ACS patients. (A) Receiver operator
characteristic (ROC) curves for (i) miR-183-5p, (ii) miR-134-5p, (iii) miR-15a-5p and (iv) let-7i-5p
in STEMI, NSTEMI and stable angina patients against healthy controls. (B) ROC curves for miR-183-5p,
iR-134-5p, iR-15a-5p, and let-7i-5p in (i) STE I and (ii) STE I patients against patients ith
stable angina. R C analysis as perfor ed using raphPad Pris version 5.0 ( raphPad Soft are,
San iego, , S ).
2.5. Discriminatory Power of the miRNA Combination Panel
An miRNA combination panel consisting of miR-134-5p, mR-15a-5p, and let-7i-5p was evaluated
for its ability in differentiating STEMI patients from the healthy controls (Figure 5). Prior to the analysis,
an miRNA score of the miRNA combination panel was calculated as described in the Methods section.
The combination had a higher discriminatory power in differentiating STEMI patients from the
healthy controls, with an AUC value of 0.935 (p < 0.0001; 95% CI, 0.737 to 0.996), a sensitivity of 100%
and a specificity of 83% (Figure 5B) when compared to that of the individual miRNAs (Figure 4A).
Furthermore, this miRNA combination panel also improved the differentiation of STEMI patients from
subjects with stable angina, with an AUC value of 0.990 (p < 0.0001; 95% CI, 0.814 to 1.000), a sensitivity
of 100% and a specificity of 91% compared to that of the individual miRNAs (Figure 5C).
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2.6. Correlation between Circulating miRNAs, Age, and Troponin I and CK- B Levels
To determine whether the expression levels of miRNAs correlate with age, plasma troponin
I, or CK-MB levels of STEMI and NSTEMI patients, Pearson correlation analyses were performed.
The expression of miR-134-5p was inversely correlated with plasma troponin I levels in ACS patients
(Pearson r = −0.586, p = 0.035, Figure 6A). In addition, correlation with plasma troponin I levels
improved with the miRNA combination panel of miR-134-5p, miR-15a-5p, and let-7i-5p (Pearson
r = −0.611, p = 0.027, Figure 6A). The expression of miR-134-5p was moderately, but not significantly
(p = 0.07), correlated with the age of patients with a Pearson r value of 0.5 (Figure 6B). For plasma
CK-MB levels or interval time of blood collection in ACS patients, no significant correlation was found
with circulating amounts of miR-183-5p, miR-134-5p, miR-15a-5p, and let-7i-5p (Figure 6C,D).
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withdrawal. Pearson correlation analyses were conducted to determine the association of expressions
of miRNAs with (A) troponin I levels, (B) age, (C) creatine kinase-myocardial band (CK-MB) levels
in STEMI and NSTEMI patients, and (D) interval time of blood collection. The miRNA combination
panel consists of miR-134-5p, mR-15a-5p, and let-7i-5p.
2.7. Expressions of miRNAs in Tissues and Organs
The expressions of miR-183-5p, miR-134-5p, miR-15a-5p, and let-7i-5p across different tissues
were estimated, using the miRNA search analysis module on microRNA Expression and Sequence
Analysis database (mESAdb) (http://konulab.fen.bilkent.edu.tr/mirna/mirna.php) to determine
their potential tissues of origin [34]. The expression of miR-183-5p is the lowest across all tissues in
comparison to miR-134-5p, miR-15a-5p, and let-7i-5p (Figure 7A). MiR-183-5p is significantly enriched
in the heart, liv r, and sk letal muscle (p < 0.05); miR-15a-5p is also significantly enriched in the heart
as well as in the bladder, colon, kidney and the immune system tissues (bone marrow, lymph node,
and spleen, p < 0.05) whereas both miR-134-5p and let-7i-5p are abundantly found in the brain and
frontal cortex.
2.8. Predicted Target Genes of miRNAs Are Enriched in Metabolic Pathways
Significant deregulation of miR-134-5p, miR-15a-5p, and let-7i-5p was observed in young STEMI
patients, therefore the union set of predicted genes for miR-134-5p, miR-15a-5p, and let-7i-5p were
selected for enrichment analysis using Enrichr [35,36], whereby the predicted genes for miR-183-5p
were submitted for enrichment analysis as described. Pathway enrichment analysis suggested that
the predicted target genes of miR-134-5p, miR-15a-5p, and let-7i-5p were enriched in the Ras/MAPK,
PI3K-AKT signaling pathway, angiogenesis, integrin, and Wnt signaling pathways which regulate cell
proliferation, cell survival, and other basic developmental processes (Figure 7B(i)). Enrichment analysis
in the Disease/Drug enrichment category in Enrichr suggested the presence of interaction between
these predicted genes with most of the risk factors of cardiovascular disease such as low-density
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lipoprotein (LDL), blood pressure, and body fat distribution as listed in Genotypes and Phenotypes
database (Figure 7B(i)). In addition, the predicted target genes of miR-183-5p include those in
Hedgehog and endothelin signaling pathways, metabolic pathways, and are associated closely with
HDL, LDL, and cholesterol metabolism (Figure 7B(ii)). The enrichment analysis of the list of predicted
genes for miR-134-5p, miR-15a-5p, let-7i-5p, and miR-183-5p, hence revealed that these miRNAs and
their predicted mRNA targets have roles aligned to events in the pathogenesis of ACS.
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Figure 7. Expressions of miRNAs in tissues and enrich ent analysis for predicted target genes of
miRNA candidates. (A) Tissues expression analysis of miRNAs was performed using the online
database of microRNA Expression and Sequence Analysis database (mESAdb) (http://konulab.fen.
bilkent.edu.tr/mirna/mirna.php). * p < 0.05 depicts significant enrichment in the respective tissue.
(B) Panther pathway and Genotypes and Phenotypes enrichment analysis for: (i) union set of predicted
target genes for miR-134-5p, miR-15a-5p and let-7i-5p and (ii) predicted target genes for miR-183-5p
were performed using the Enrichr online algorithm program. Combined enrichment scores which
integrate p-value and z-score information as described in Section 4.8 were used to rank the enrichment
term in analysis. The top 10 enrichment terms are reported for each bar graph. Abbreviations:
BM, Bone Marrow; B, Brain; H, Heart; K, Kidney; Li, Liver; Lu, Lungs; Pa, Pancreas; Pr, Prostate;
SM, Skeletal muscle; Sp, Spleen; Th, Thymus; FC, Frontal Cortex; Ly, Lymph node; Co, Colon; Bl,
Bladder; Te, Testicle; A, Adrenal gland; SI, Small intestine; HDL, high-density lipoproteins; and LDL,
low-density lipoproteins.
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3. Discussion
The role of miRNAs in the pathophysiology of atherosclerosis and CAD has received increasing
attention. MiRNAs modulate endothelial function, communication between endothelial cells and
vascular smooth muscle cells, differentiation of the latter, and regulation of inflammatory cells in blood
vessels, all of which are events leading to the development of CAD [37,38]. Deregulated expressions
of cardiac specific miRNAs such as miR-1, miR-499, miR-133a/b, miR-208a/b, and miR-145 have
been established in patients with stable CAD, ACS, and AMI, and their roles in events (regulation
of endothelial function, differentiation of vascular smooth muscle cells, and plaques stabilization)
leading to the development of these diseases are documented [39]. However, some cardiac-specific
miRNAs such as miR-1, miR-133b, and miR-499 may have less discriminative power for AMI and
unstable angina as they can also be released from injured skeletal muscles and thus conditions other
than acute myocardial necrosis may influence their circulating levels [40]. Despite this limitation,
in a large cohort of ACS patients, the levels of miR-132, miR-140-3p, and miR-210 predicted mortality,
further highlighting the value of using miRNAs for disease prognosis [41], and underscoring the need
for further identification of miRNAs for disease stratification and more accurate diagnosis.
The present study was undertaken to identify plasma miRNAs in young individuals diagnosed
with ACS in Malaysia. From an initial list of top 13 up-regulated and 16 down-regulated miRNAs
identified by sRNA-seq with differential expression analysis of FDR < 10% from the STEMI group,
subsequent validation in the qRT-PCR cohort revealed significantly lower expressions of miR-134-5p,
miR-15a-5p, and let-7i-5p in patients with STEMI, and higher expression of miR-183-5p in NSTEMI
patients, compared to healthy controls. However, cardiac-specific miRNAs (e.g., miR-1, miR-208a,
miR-208b, miR-133a, miR-133b, and miR-499), smooth muscle-enriched miR-143 and miR145 (released
from injured cardiomyocytes), inflammation-associated miR-155, vascular protective miR-126 and
endothelial-enriched miR-17 and 92a [40,42–51] were absent in the list of significantly deregulated
plasma miRNAs as identified by sRNA-seq, possibly because of low sequencing reads. Indeed,
qRT-PCR quantification revealed that these miRNAs are present in relatively low abundance in the
plasma of ACS subjects [22].
Previously, let-7i-5p and miR-15a-5p were reported to be deregulated in CAD [52–54]. Significant
down-regulation of let-7i was observed in elderly patients with stable CAD in comparison to healthy
controls [52,54]. However, in the present cohort of young patients, let-7i-5p did not discriminate stable
angina from healthy controls but instead identified the STEMI from the healthy control and stable
angina groups. Members of the let-7 family share the same seed sequence and are conserved [55].
It has been reported that let-7g preserves endothelial function and suppresses inflammation induced
by metabolic deregulation [56]. Indeed, pathway enrichment analysis showed that targets of let-7i-5p
are involved in angiogenesis and metabolic pathways. In addition, this miRNA is also significantly
enriched in lymph nodes and the spleen, which is suggestive of its potential role in inflammation.
The expression of miR-15a-5p is up-regulated in the plasma of elderly stable CAD (non-occlusive)
patients when compared to healthy controls [53]. However, its differential expression was significantly
different between the present young patients with stable angina (occlusive) and healthy controls.
MiR-15a-5p has instead discriminated the STEMI from the healthy control and stable angina groups.
These observations suggest that age factors or the differences between CAD presentations (occlusive
versus non-occlusive) may lead to the differential expression of these miRNAs. Likewise, miR-15a-5p
is also abundantly expressed in the bone marrow, lymph nodes and the spleen and, together with
let-7i-5p and miR-134-5p, addresses predicted targets genes that are involved in endothelin signaling
pathways, metabolic pathways, and lipid metabolism. In addition, miR-15a-5p is also significantly
enriched in the heart, suggesting that it could potentially be cardio-specific. The ability of both let-7i-5p
and miR-15a-5p in discriminating STEMI from stable angina and healthy controls warrants further
evaluation of their potentials for the diagnosis of STEMI.
MiR-134-5p has been identified in plasma or serum of patients with STEMI, NSTEMI, unstable
angina pectoris, acute myocardial infarction, and acute pulmonary embolism [17,18,20]. An earlier
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study showed a 6-fold increase in miR-134-5p expression, six hours after the onset of symptoms [57]
while a kinetic study reported its peaked expression (6-fold) on admission [20]. In the present study,
the expression of miR-134-5p was lower in STEMI and NSTEMI patients compared to healthy controls.
The expression was measured approximately 36 h after the onset of symptoms, an average time needed
for stabilization of the patients in the clinical ward, examination by ECG and percutaneous coronary
angiogram. Nevertheless, the expression of miR-134-5p remained detectable and could discriminate
the STEMI patients from healthy controls and stable angina patients with a relatively high AUC
value, in agreement with a previous report [22]. Pearson analysis revealed no correlation between
the expression of miR-134-5p and the time after the onset of symptoms at which blood was collected.
However, one could still argue that a late sampling time may have contributed to the lower expression
level of miR-134-5p in the present study, compared to earlier finding [22]. The kinetic study mentioned
above [20] showed a 1.6-fold increase in expression 22 h after symptoms onset in patients with acute
myocardial infarction; thus, despite a gradual decline in miR-134-5p expression with time, it still can
be expected to be above baseline at the moment that blood was sampled for the present experiments.
Hence, contrary to the higher expression reported in older ACS patient group [20,22], miR-134 levels
are indeed lower in the young ACS group compared to healthy controls. MiR-134-5p accelerates
atherosclerosis by promoting lipid accumulation and inflammatory responses following induction of
lipoprotein lipase in macrophages [58], which explains its higher (3.5-fold) expression in peripheral
blood mononuclear cells isolated from patients with unstable angina [17]. Endothelium-expressed
miRNAs such as miR-126, -17, -92a, and inflammatory-associated miR-155 are also reduced in the
blood of patients with stable CAD, suggesting that these miRNAs are taken up into the atherosclerotic
lesions [52]. In this regard, it has been reported that macrophages in atherosclerotic lesions express
scavenger receptors (SRs) for the uptake of oxidized low-density lipoproteins and several miRNAs
have been shown to regulate SRs in atherosclerosis [59]. Hence, it appears worthwhile to investigate
the role of miR-134-5p from this aspect as well. Combining miR-134-5p with miR-15a-5p and let-7i-5p
improved the power of discriminating STEMI patients from those with stable angina with the highest
AUC value compared to those of the individual miRNAs. This is not surprising given that each miRNA
has multiple targets and multiple miRNAs can act in a cooperative way to modulate events related to
CAD pathogenesis as indicated by the present target genes enrichment analysis. Thus, the use of a
combination of multiple miRNAs could achieve greater diagnostic power for ACS.
MiR-183-5p plays an important role in maintaining endothelial barrier function and vascular
permeability [60], even though it is better known as an oncomir [61–64] and is overexpressed in tumor
tissues. MiR-183-5p regulates the tightness of the blood-nerve barrier [65] by regulating claudin-5
protein, an endothelial cell-specific tight junction component [66]. The expression of miR-183-3p is
down-regulated in plasma of heart failure patients, suggesting that miR-183 could potentially be a
marker of heart failure [67]. Indeed, the present tissue expression analysis revealed that miR-183 is
enriched in the heart and skeletal muscle. The significant up-regulation of miR-183-5p in plasma of
NSTEMI patients in the present study could potentially be related to its effects on the endothelial
barrier, particularly on the tight junction proteins during atherogenesis, but this warrants future
investigations. If indeed miR-183-5p is involved in atherogenesis, it could potentially serve as an early
marker for ACS patients without malignancy. Nevertheless, since it is enriched in skeletal muscle, its
circulating levels may be impacted by conditions involving injury of those tissues.
Several limitations of the present study merit consideration. First, the study was limited by a small
cohort size given that we could recruit only a small number of patients below 45 years of age due to the
relatively lower prevalence of ACS in younger age groups (23%) compared to older age groups (77%).
Due to this low number, we were also unable to stratify the cohort according to ethnic groups to further
identify ethnicity-related miRNAs. The expression of miR-375 and its CpG methylation is significantly
different between the Han and Kazak ethnic groups of type 2 diabetes patients [68]. MiR-375 was
also identified by the present sRNA-seq but further evaluation of its expression by qRT-PCR yielded
insignificance. In another example, polymorphism within the miR-155 binding site on the 3′UTR of
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its target gene, angiotensin II type 1 receptor (AGTR1) has been identified in different ethnic groups.
This polymorphism can disrupt miR-155 regulation of AGTR1, leading to increased expression which
contributes to vasoconstriction and increases the risk for cardiovascular disease [69,70]. In Malaysia,
the Indian ethnic group has the highest prevalence of ACS followed by the Malay and Chinese groups
and hence, a larger cohort that enables ethnic group stratification would be required to determine
whether or not the miRNAs identified in the present study are ethnically differently distributed.
Second, we observed discrepancies between the expression trend for miR-183-5p and miR-15a-5p
analyzed by sRNA-seq and qRT-PCR. The sRNA-seq analysis showed up-regulation of miR-183-5p for
STEMI patients but qRT-PCR validation revealed increased miR-183-5p expression only in NSTEMI
patients. Likewise, for miR-15a-5p, the sRNA-seq analysis showed up-regulation in STEMI patients
but the qRT-PCR validation instead revealed down-regulation in STEMI patients. These discrepancies
probably reflect the higher sensitivity and sequence-specificity of qRT-PCR, which can quantify absolute
copies numbers of specific mRNA or small RNA species, whereas, with the RNA-seq method, miRNA
quantification is expressed as a value relative to the total number of sequences reads of a given sample.
Hence, for miRNAs with a high variance in expression distribution across samples, comparisons
between the latter may not yield reliable results [71].
Third, we did not perform statistical correction for confounding factors as the number of
subjects in each group was low. It has been reported that plasma levels of cardiomyocyte-specific
miRNAs such as miR-208b and miR-499 are not affected by a wide range of clinical confounders
such as age, gender, body mass index, kidney function, systolic blood pressure, and white blood
cell count [45]. However, confounding factors such as medication (including statins) influence the
events involved in the pathophysiology of cardiovascular diseases by regulating the expression of
particular miRNAs. For example, simvastatin can decrease miR-155 expression by disrupting the
mevalonate-geranylgeranyl-pyrophosphate-RhoA signaling pathway leading to endothelial nitric
oxide synthase expression and endothelium-dependent vasodilatation [72]. Atorvastatin induces let-7i
expression and down-regulates toll-like receptor 4 signaling in monocytes from CAD patients thereby
blunting immune responses [54]. Similarly, in statin-treated unstable angina patients, miRNAs such as
miR-15b, -17, -20a and -93 that primarily target genes involved in angiogenesis are down-regulated,
in line with the atheroprotective effects of statins in these patients [73]. Hence, these findings highlight
the importance of statistical corrections for the effect of medications in future larger cohort studies.
Last, the present study did not perform time course measurements of the changes in the levels
of the identified miRNAs, which would provide the optimal detection window to identify their
dynamic contribution.
4. Materials and Methods
4.1. Participants
Recruitment of participants was conducted at the University Malaya Medical Centre, Kuala
Lumpur, Malaysia in accordance to the approved guidelines by the local Medical Ethics Committee
(Ethics No. 889.6, November 2011). Informed consent was obtained from all subjects.
For sRNA-seq, 14 ACS male patients below 45 years of age, clinically diagnosed with either
NSTEMI or STEMI, and 14 gender- and age-matched control subjects were enrolled in this first cohort.
The diagnosis of STEMI and NSTEMI in this study is based on local guidelines. STEMI is defined as
persistent ST segment elevation ≥ 1 mm in two contiguous electrocardiographic leads, or the presence
of a new left bundle branch block in the setting of positive cardiac markers. NSTEMI is defined as the
occurrence of acute myocardial infarction in the setting of positive cardiac markers, with or without
accompanying electrocardiographic changes other than ST-segment elevation [74,75]. The healthy
controls had proven normal coronary via invasive percutaneous coronary angiogram.
For qRT-PCR validation, 14 ACS patients, 12 healthy control subjects and 12 aged-matched stable
angina patients were recruited in this second cohort. The stable angina patients previously had CAD
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confirmed by percutaneous coronary angiogram but had not presented with acute episodes for more
than one year.
Exclusion criteria for the ACS and stable angina groups include previous history of cardiovascular
diseases such as myocardial infarction, heart failure and cardiomyopathy. For the selection of healthy
subjects, chronic alcoholics, smokers and those with family history of cardiovascular disease (CVD) or
on CVD medications and familial hypercholesterolemia were excluded. Only males were included in
the present study to preserve data homogeneity.
4.2. Isolation of Human Plasma
For confirmed cases of STEMI, NSTEMI and stable angina, blood collection was performed within
36 h after admission. Whole blood samples (6 mL) were collected by direct venous puncture into tubes
containing ethylenediaminetetraacetic acid (EDTA), centrifuged at 2000× g for 15 min after which
the supernatant (plasma) was carefully transferred into an RNase-free tube for extraction of miRNAs.
The resultant plasma was aliquoted into cryopreservation tubes and stored at −80 ◦C until use.
4.3. MiRNA Extraction
MiRNAs were extracted from plasma using the miRNeasy serum/plasma kit (Qiagen, Hilden,
Germany), and finally eluted into 14µL of RNase-free water according to the manufacturer’s
instructions. Subsequently, the miRNA samples were concentrated using refrigerated CentriVap
benchtop centrifugal concentrator (Labconco Corporation, Kansas City, MI, USA). An Agilent Small
RNA Kit was used to verify miRNA quality and quantity using Agilent 2100 Bioanalyzer (Agilent
Technologies, Santa Clara, CA, USA).
4.4. Small-RNA Sequencing (sRNA-seq)
Library preparation and sRNA sequencing was performed on each plasma sample using the
Illumina platform, following the manufacturer’s protocol (Illumina Inc., San Diego, CA, USA). Small
RNA libraries were constructed using a TruSeq Small RNA Sample Preparation kit (Illumina) according
to the manufacturer’s instructions. Briefly, small RNA samples (18–30 nt) were gel-purified and ligated
to the 5′ and 3′ adapters, followed by RT-PCR for cDNA library construction and incorporation of
index tags. The cDNA library fragments were purified, separated on a PAGE gel and loaded on
an Agilent Technologies 2100 Bioanalyzer to check size, purity, and concentration. Libraries were
sequenced using Illumina HiSeq2000 at the BGI-Shenzhen (Shenzhen, Guangdong, China).
4.5. Sequencing Data Analysis
The read data were assessed and pre-processed using FastQC (http://www.bioinformatics.
babraham.ac.uk/projects/fastqc) and FASTX-Toolkit (http://hannonlab.cshl.edu/fastx_toolkit),
respectively. Briefly, the 3′ adapter sequences and low quality bases (<Q30) were trimmed. All reads
that were shorter than 18 bp or containing unknown bases (N) were discarded. For each dataset,
reads with identical sequences were collapsed to give a set of non-redundant reads (nr-reads).
The nr-reads were then aligned to the human genome (GRCh37) using the mapper module from
miRDeep2 [76] by allowing one mismatch. Unmapped reads/nr-reads or reads/nr-reads mapped
to more than five regions in the human genome were filtered. The distribution of mapped
reads was analyzed by cross-checking with miRBase v20 (http://www.mirbase.org/), Ensembl
annotations and Rfam v11 database (http://rfam.xfam.org/). Finally, the miRDeep2 program
(https://www.mdc-berlin.de/content/mirdeep2-documentation) [76] was used to identify known
miRNAs (based on miRNA data from miRBase v20) to predict novel miRNAs and to summarize
the read counts for each miRNA in every sample. The comma separated values (csv) files for
miRNA expression from mirDeep2 were obtained for further analysis. Differential expression of the
miRNA-Seq raw count data was assessed using the BioC/R package DESeq2 (https://bioconductor.
org/packages/release/bioc/html/DESeq2.html) [32]. The data were adjusted to a common scale
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by normalizing them for different library sizes. The data (miRNA) dispersion from the mean was
estimated, which provides the basis for inference. p-values were adjusted using multiple testing with
the Benjamini and Hochberg (1995) approach by applying the FDR of 10% [77]. The list or miRNAs
with adjusted p-values were filtered at p = 0.1.
4.6. Validation of miRNA by qRT-PCR
To validate the result of sRNA-seq data analysis, two-step qRT-PCR was performed to quantitate
the expression of selected miRNAs. For reverse transcription, a total input of 10 ng of total RNA
was used to synthesize cDNA using a Taqman miRNA Reverse Transcription Kit according to the
manufacturer’s instructions (Applied Biosystems, Foster City, CA, USA). Taqman miRNA Assay
for miR-183-5p (Assay ID: 002269), miR-134-5p (Assay ID: 001186), miR-15a-5p (Assay ID: 000389),
let-7i-5p (Assay ID: 002221), miR-375 (Assay ID: 000564) and miR-1307-5p (Assay ID: 47256_mat) were
purchased from Applied Biosystems. Taqman Fast Advance PCR Master Mix (Applied Biosystems)
was used to perform the real-time RT-PCR. As it is reported that specific small nuclear RNA and
small nucleolar RNA such as RNU44, RNU68 and RNU6 are highly variable or not detectable
in human plasma [61,62] and there is still no consensus on a suitable reference miRNA that can
be used for qRT-PCR normalization, candidate reference miRNAs such as miR-320a (Assay ID:
002277) and miR-17-5p (Assay-ID: 000393) were selected as endogenous references based on their
consistent expressions in sRNA-seq analysis. The expression stability of both reference miRNAs
were also analyzed using geNorm and normalization by multiple reference genes was performed
as proposed by Hellemans et al. (2007) [78,79]. Briefly, normalized relative quantity (NRQ) values
were obtained by dividing the relative quantity (RQ) of the target miRNA with a normalizing factor
(NF). NF was calculated from the geometric mean of RQ of the two reference miRNAs in each
sample. RQ of target miRNAs in each sample was calculated using the equation: RQ = E∆Ct and
∆Ct = Ctmean sample − Ctsample whereby, E refers to the amplification efficiency of the primer and Ct
refers to the cycle threshold value in qRT-PCR. Log2-transformed NRQ values, representing the
expression of target miRNAs were used to plot graphs.
4.7. Tissue Expression Analysis of miRNA Candidates
The expressions of miR-183-5p, miR-134-5p, miR-15a-5p, and let-7i-5p across different tissues
were analyzed using the miRNA search analysis module on mESAdb [34] which is accessible at
http://konulab.fen.bilkent.edu.tr/mirna/mirna.php. Normalized mean expressions obtained from
a dataset comprising of normal human tissues and organs by Baskerville et al. [80] was analyzed.
p < 0.05 depicts significant enrichment in the respective tissue.
4.8. Target Genes Prediction and Gene List Enrichment Analysis for miRNA Candidates
The target genes of miR-183-5p, miR-134-5p, miR-15a-5p and let-7i-5p were predicted using
TargetScan [81] database. The target genes predicted were selected for subsequent pathway and
gene ontology enrichment analysis using Enrichr [35,36]. Adjusted p-values, z-score, and combined
enrichment score were computed by Enrichr. The combined enrichment score was described as
a combination of the p-value and z-score calculated as c = ln(p) × z, whereby, c is the combined
enrichment score, p is the p-value computed by Fisher’s exact test and z is the z-score computed in
order to access the deviation from the expected rank. The combined enrichment score was used to
rank the enrichment terms in the analysis.
4.9. Statistical Analysis
Quantitative data were first evaluated to determine whether or not they followed Gaussian
distribution using the D’Agostino and Pearson omnibus and Shapiro-Wilk normality test [82–85].
For p-value greater than the alpha level of 0.05, the null hypothesis that the data reflect a normally
distributed population cannot be rejected. Therefore, one-way ANOVA followed by the Tukey multiple
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groups comparison test was performed for normally distributed data whereas the non-parametric
Kruskal Wallis test was used for data not distributed normally. In addition, qualitative data were
compared using the Chi-Square test. Statistical analysis and p-values were computed using GraphPad
Prism version 5.0 (GraphPad Software, San Diego, CA, USA). Statistical significance of differences was
accepted at p < 0.05.
ROC curve analysis and AUC were performed to discriminate healthy controls from patients
with STEMI, NSTEMI or stable angina and to investigate the diagnostic accuracy of selected miRNAs.
Standard errors of AUCs and 95% confidence intervals (95% CI) were computed following the method
of DeLong et al. (1988) [33]. Based on ROC analysis, the sensitivity and specificity of miRNAs were
evaluated via cut-off points obtained from the Youden index computed using MedCalc software
version 16.8.4 (MedCalc Software, Ostend, Belgium) [20,86]. In addition, correlation analyses between
the miRNAs with patients’ age, plasma troponin I and CK-MB levels were evaluated using Pearson’s
correlation coefficient. To perform ROC and Pearson’s correlation analyses for the miRNA combination
panel (miR-134-5p, miR-15a-5p and let-7i-5p), a miRNA score representing the cumulative expression
of each miRNA in the panel was computed first as described by Goren et al. (2012), whereby the score
for each sample is the sum of the inverted-normalized signals of each individual miRNA adjusted by
subtracting a constant (the minimal score) so that the range of scores starts at 0 [87].
5. Conclusions
In conclusion, findings from sRNA-seq and qRT-PCR revealed a novel miRNA expression profile
in young individuals with ACS compared to those of previous studies in patients of older age groups.
MiR-183-5p emerged as the circulating miRNA that can significantly discriminate NSTEMI from STEMI,
stable angina patients or healthy normal individuals whereas miR-134-5p could discriminate STEMI
patients from healthy individuals. In addition, the combination panel, which include miR-134-5p,
miR-15a-5p, and let-7i-5p scored better discriminatory power in differentiating STEMI patients from
healthy controls. Procedural intervention for STEMI and NSTEMI are different. Hence, miRNAs that
can discriminate between the two will aid in obtaining accurate intervention decision. Nevertheless,
before these miRNAs can be used in clinical settings for diagnosis and/or therapeutic decision-making,
evaluation in future trials with greater statistical power is warranted. CAD-associated miRNAs could
be used to complement rather than to replace current diagnostic procedures to achieve rapid and
greater accuracy in the stratification of ACS. In addition, elucidation is needed of the roles of these
miRNAs in endothelial dysfunction, inflammation, cholesterol metabolism, and atherogenesis to
provide clearer understandings to their contribution to the development and progression of ACS.
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